AR015445A1 - Metodo para preparar un compuesto derivado de quinolina, dichos compuestos y compuestos intermediarios - Google Patents
Metodo para preparar un compuesto derivado de quinolina, dichos compuestos y compuestos intermediariosInfo
- Publication number
- AR015445A1 AR015445A1 ARP980104603A ARP980104603A AR015445A1 AR 015445 A1 AR015445 A1 AR 015445A1 AR P980104603 A ARP980104603 A AR P980104603A AR P980104603 A ARP980104603 A AR P980104603A AR 015445 A1 AR015445 A1 AR 015445A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- optionally substituted
- ring
- alkylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Un método para preparar un compuesto derivado de la quinolina de formula (I) o una de sus formas salificadas farmacéuticamente aceptables, en la que: Ar esun grupo fenilo opcionalmente sustituido, o un grupo naftilo o cicloalcadienilo C5-7, o un grupo heterocíclico de un solo anillo o de anillos condensados,opcionalmente sustituido, que tiene carácter aromático, que contiene de 5 a 12 átomos en el anillo y que comprende hasta cuatro heteroátomos en el anillo o encada uno de ellos, seleccionadosentre S, O y N; R es alquilo C1-8 lineal o ramificado, cicloalquilo C3-7, cicloalquilalquilo C4-7, un grupo feniloopcionalmente sustituido o un grupo fenil-alquilo C1-6, un anillo heteroaromático de 5 miembros, opcionalmente sustituido, que comprendehasta 4 heteroátomosseleccionados entre O y N, hidroxi-alquilo C1-6, di-alquil C1-6-aminoalquilo, acil C1-6-aminoalquilo, alcoxi C1-6-alquilo, alquil C1-6-carbonilo, carboxi,alcoxi C1-6-carbonilo, alcoxi C1-6-carbonil-alquilo C1-6, aminocarbonilo, alquil C1-6-aminocarbonilo, di-alquil C1-6-aminocarbonilo; o un grupo -(CH2)p- cuandocierra un ciclo con Ar, en el que p es 2 o 3; R1 y R2, que pueden ser iguales o diferentes, son independientemente hidrogeno o alquilo C1-6 lineal o ramificadoo juntos forman un grupo -(CH2)n- en la que n representa 3, 4 o 5; o R1 junto con R forma un grupo -(CH2)q, en el que q es 2, 3, 4 o 5; R3 y R4, que pueden seriguales o diferentes, son independientemente hidrogeno, alquilo C1-6 lineal o ramificado, alquenilo C1-6, arilo, alcoxi C1-6, hidroxi, halogeno, nitro, ciano,carboxi, carboxamido, sulfonamido, trifluorometilo, amino, mono- y di-alquil C1-6-amino, -O(CH2)r-NT2, en que r es 2, 3 o 4 y T es alquilo C1-6 o forma ungrupo heterocíclico de formulas (II)o (III), en los que V y V1 son hidrogeno y u es 0, 1 o 2; -O(CH2)s-OW2, en el que s es 2, 3 o 4 y W es alquilo C1-6,hidroxialquilo, mono- o di-alquilaminoalquilo, acilamino, alquilsulfonilamino, aminoacilamino, mono- o di-alquilaminoacilamino; estando presentes en el nucleode quinolina hasta 4 sustituyentes R3; o R4 es un grupo -(CH2)t- cuando cierra un ciclo con R5 cuando es arilo, en el que t es 1, 2 o 3; y R5 es alquilo C1-6
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5930397P | 1997-09-17 | 1997-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015445A1 true AR015445A1 (es) | 2001-05-02 |
Family
ID=22022126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104603A AR015445A1 (es) | 1997-09-17 | 1998-09-16 | Metodo para preparar un compuesto derivado de quinolina, dichos compuestos y compuestos intermediarios |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US6335448B1 (es) |
| EP (1) | EP1017676B1 (es) |
| JP (1) | JP2001516744A (es) |
| KR (1) | KR20010024031A (es) |
| CN (1) | CN1125815C (es) |
| AP (1) | AP1201A (es) |
| AR (1) | AR015445A1 (es) |
| AT (1) | ATE353879T1 (es) |
| AU (1) | AU744538B2 (es) |
| BG (1) | BG104243A (es) |
| BR (1) | BR9812085A (es) |
| CA (1) | CA2303026A1 (es) |
| DE (1) | DE69837100T2 (es) |
| DZ (1) | DZ2607A1 (es) |
| EA (1) | EA002633B1 (es) |
| ES (1) | ES2283072T3 (es) |
| HU (1) | HUP0004855A3 (es) |
| ID (1) | ID24140A (es) |
| IL (1) | IL134991A0 (es) |
| MA (1) | MA24644A1 (es) |
| MY (1) | MY120237A (es) |
| NO (1) | NO314303B1 (es) |
| NZ (1) | NZ503307A (es) |
| OA (1) | OA11340A (es) |
| PE (1) | PE129299A1 (es) |
| PL (1) | PL339340A1 (es) |
| SK (1) | SK3672000A3 (es) |
| TR (1) | TR200000720T2 (es) |
| TW (1) | TW509678B (es) |
| UY (2) | UY25174A1 (es) |
| WO (1) | WO1999014196A1 (es) |
| ZA (1) | ZA988455B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1201A (en) * | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
| CA2368455A1 (en) | 1999-03-29 | 2000-10-05 | Neurogen Corporation | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
| JP2007520543A (ja) | 2004-02-04 | 2007-07-26 | ファイザー・プロダクツ・インク | 置換キノリン化合物 |
| CA2611060A1 (en) * | 2005-06-03 | 2006-12-07 | R. Thomas Simpson | Quinoline derivatives as nk3 antagonists |
| WO2007016609A2 (en) * | 2005-08-02 | 2007-02-08 | Smithkline Beecham Corporation | Method for the synthesis of quinoliνe derivatives |
| EP1915363A1 (en) * | 2005-08-11 | 2008-04-30 | AstraZeneca AB | Oxopyridyl quinoline amides as nk3 receptor modulators |
| CN101268052A (zh) * | 2005-09-21 | 2008-09-17 | 阿斯利康(瑞典)有限公司 | 作为nk-3受体配体的n-氧代-杂环和n-氧代-烷基喹啉-4-甲酰胺 |
| AR057130A1 (es) * | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
| US20090054445A1 (en) * | 2006-01-27 | 2009-02-26 | Astrazeneca Ab | Amide Substituted Quinolines |
| CN102702099A (zh) * | 2012-06-21 | 2012-10-03 | 江苏恩华药业股份有限公司 | (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法 |
| CN102924375B (zh) * | 2012-06-21 | 2015-02-18 | 江苏恩华药业股份有限公司 | Talnetant中间体及其制备方法和应用 |
| CN103214416A (zh) * | 2013-04-26 | 2013-07-24 | 扬州大学 | 一种合成多取代喹啉类化合物的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2776290A (en) * | 1957-01-01 | Hydroxy cevchoninates and carboxylic | ||
| SK282722B6 (sk) * | 1994-05-27 | 2002-11-06 | Smithkline Beecham S.P.A. | N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie |
| US5627193A (en) * | 1995-02-09 | 1997-05-06 | Mitsui Toatsu Chemicals, Inc. | Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds |
| AP1201A (en) * | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
-
1998
- 1998-05-08 AP APAP/P/2000/001767A patent/AP1201A/en active
- 1998-09-08 UY UY25174A patent/UY25174A1/es not_active Application Discontinuation
- 1998-09-08 MA MA25246A patent/MA24644A1/fr unknown
- 1998-09-11 PE PE1998000868A patent/PE129299A1/es not_active Application Discontinuation
- 1998-09-14 DZ DZ980217A patent/DZ2607A1/xx active
- 1998-09-15 MY MYPI98004207A patent/MY120237A/en unknown
- 1998-09-16 ZA ZA988455A patent/ZA988455B/xx unknown
- 1998-09-16 AR ARP980104603A patent/AR015445A1/es not_active Application Discontinuation
- 1998-09-17 AU AU93958/98A patent/AU744538B2/en not_active Ceased
- 1998-09-17 DE DE69837100T patent/DE69837100T2/de not_active Expired - Lifetime
- 1998-09-17 TR TR2000/00720T patent/TR200000720T2/xx unknown
- 1998-09-17 EA EA200000322A patent/EA002633B1/ru not_active IP Right Cessation
- 1998-09-17 KR KR1020007002766A patent/KR20010024031A/ko not_active Application Discontinuation
- 1998-09-17 ES ES98947099T patent/ES2283072T3/es not_active Expired - Lifetime
- 1998-09-17 WO PCT/US1998/019434 patent/WO1999014196A1/en active IP Right Grant
- 1998-09-17 CA CA002303026A patent/CA2303026A1/en not_active Abandoned
- 1998-09-17 CN CN98810978A patent/CN1125815C/zh not_active Expired - Fee Related
- 1998-09-17 JP JP2000511747A patent/JP2001516744A/ja active Pending
- 1998-09-17 HU HU0004855A patent/HUP0004855A3/hu unknown
- 1998-09-17 SK SK367-2000A patent/SK3672000A3/sk unknown
- 1998-09-17 AT AT98947099T patent/ATE353879T1/de not_active IP Right Cessation
- 1998-09-17 NZ NZ503307A patent/NZ503307A/en unknown
- 1998-09-17 BR BR9812085-9A patent/BR9812085A/pt not_active IP Right Cessation
- 1998-09-17 PL PL98339340A patent/PL339340A1/xx unknown
- 1998-09-17 IL IL13499198A patent/IL134991A0/xx unknown
- 1998-09-17 EP EP98947099A patent/EP1017676B1/en not_active Expired - Lifetime
- 1998-09-17 US US09/508,358 patent/US6335448B1/en not_active Expired - Fee Related
- 1998-09-17 ID IDW20000498A patent/ID24140A/id unknown
- 1998-09-29 TW TW087114858A patent/TW509678B/zh not_active IP Right Cessation
-
1999
- 1999-02-26 UY UY25407A patent/UY25407A1/es unknown
-
2000
- 2000-03-15 BG BG104243A patent/BG104243A/xx unknown
- 2000-03-16 NO NO20001387A patent/NO314303B1/no not_active IP Right Cessation
- 2000-03-16 OA OA1200000078A patent/OA11340A/en unknown
-
2001
- 2001-10-17 US US09/981,185 patent/US20020038029A1/en not_active Abandoned
-
2002
- 2002-06-17 US US10/174,458 patent/US20020173657A1/en not_active Abandoned
-
2003
- 2003-05-20 US US10/441,708 patent/US20040049031A1/en not_active Abandoned
-
2005
- 2005-03-30 US US11/093,701 patent/US20050171152A1/en not_active Abandoned
-
2006
- 2006-04-28 US US11/413,932 patent/US20060189809A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015445A1 (es) | Metodo para preparar un compuesto derivado de quinolina, dichos compuestos y compuestos intermediarios | |
| AR004972A1 (es) | Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado. | |
| AR004735A1 (es) | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| CR8808A (es) | Inhibidores de cept | |
| CO5271658A1 (es) | Antagonistas del factor liberador de corticotropina | |
| AR012732A1 (es) | Derivados de fenilquinolinas, procedimientos para su preparacion, composiciones farmaceuticas, y su uso para la fabricacion de medicamentos | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| AR021354A1 (es) | Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica | |
| AR027402A1 (es) | Derivados de pirimidina. | |
| CO5560560A2 (es) | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
| AR034669A1 (es) | Derivados de tetrahidroquinolina y su uso para controlar la fertilidad | |
| AR033306A1 (es) | Compuestos | |
| RS50290B (sr) | Novi derivati 1,3-dihidro-2h-indol-2-ona i njihova upotreba kao liganada za v1b i v1a receptore arginin-vazopresina | |
| AR046938A1 (es) | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| AR023703A1 (es) | N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa | |
| AR014868A1 (es) | UN COMPUESTO DERIVADO DE N,N ( SUSTITUIDO) FENIL (ARILO O HETEROARILO) PROPANAMINA, UNA COMPOSICIoN FARMACÉUTICA, USO DE DICHO COMPUESTO Y UN MÉTODO PARA PREPARARLO. | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| AR004706A1 (es) | Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo. | |
| CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
| CO5540284A2 (es) | Sulfonamidas | |
| AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
| AR004970A1 (es) | Sales de derivados de la quinolina, composiciones farmaceuticas que comprenden dichas sales y procedimientos para preparar dichas sales. | |
| AR027744A1 (es) | Compuestos de eter difenilico utiles en terapia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |